Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia - PubMed (original) (raw)
. 2004 Feb;202(2):233-40.
doi: 10.1002/path.1503.
Affiliations
- PMID: 14743506
- DOI: 10.1002/path.1503
Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia
Gyeong Hoon Kang et al. J Pathol. 2004 Feb.
Abstract
To date, several reports have been published about CpG island methylation of various genes in prostate cancer. However, most of these studies have focused on cancer tissue only or a single gene and data about concurrent methylation of multiple genes in prostate cancer or prostatic intraepithelial neoplasia (PIN) are limited. The aim of the present study was to determine the methylation profile of 11 tumour-related genes in prostate cancer and PIN. Seventy-one samples, including 37 prostate cancers, 14 PINs, and 20 normal prostates, were examined for the methylation status of 11 tumour-related genes using methylation-specific PCR. The mean number of genes methylated was significantly higher in prostate cancer and PIN than in non-neoplastic prostate (4.4, 3, and 0.2, respectively; p < 0.001). In prostate cancer, APC, GSTP1, MGMT, and RASSF1A were frequently methylated at a frequency of 56.8%, 86.5%, 75.7%, and 83.8%, respectively. These genes were methylated in more than 30% of PINs. Prostate cancers with high serum prostate-specific antigen (PSA) (more than 8 ng/ml) or a high Gleason score (GS) (3 + 4 or more) showed higher numbers of methylated genes than those with low serum PSA (8 or less) or low GS (3 + 3 or less) (5.4 versus 2.5 and 5.4 versus 3.1, respectively; p < 0.05). The methylation frequency of APC, RASSF1A, and RUNX3 was higher in prostate cancers with high serum PSA or with high GS than in those with low PSA or with low GS, respectively, the differences reaching statistical significance (p < 0.05). A strong association between MGMT methylation and loss of MGMT expression was demonstrated by immunohistochemistry. CpG island methylation is a frequent event, occurs early, and accumulates during multi-step prostatic carcinogenesis. High levels of CpG island hypermethylation might serve as a potential biological marker for aggressive prostate cancer.
Copyright 2004 John Wiley & Sons, Ltd.
Similar articles
- Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, Kim D, Kang GH. Cho NY, et al. J Pathol. 2007 Feb;211(3):269-77. doi: 10.1002/path.2106. J Pathol. 2007. PMID: 17139617 - Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.
Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF. Maruyama R, et al. Clin Cancer Res. 2002 Feb;8(2):514-9. Clin Cancer Res. 2002. PMID: 11839671 - A quantitative promoter methylation profile of prostate cancer.
Jerónimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, Oliveira J, Teixeira MR, Lopes C, Sidransky D. Jerónimo C, et al. Clin Cancer Res. 2004 Dec 15;10(24):8472-8. doi: 10.1158/1078-0432.CCR-04-0894. Clin Cancer Res. 2004. PMID: 15623627 - GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.
Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. Nakayama M, et al. J Cell Biochem. 2004 Feb 15;91(3):540-52. doi: 10.1002/jcb.10740. J Cell Biochem. 2004. PMID: 14755684 Review. - Molecular biomarker in prostate cancer: the role of CpG island hypermethylation.
Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, Nelson WG. Bastian PJ, et al. Eur Urol. 2004 Dec;46(6):698-708. doi: 10.1016/j.eururo.2004.07.022. Eur Urol. 2004. PMID: 15548435 Review.
Cited by
- GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications.
Martignano F, Gurioli G, Salvi S, Calistri D, Costantini M, Gunelli R, De Giorgi U, Foca F, Casadio V. Martignano F, et al. Dis Markers. 2016;2016:4358292. doi: 10.1155/2016/4358292. Epub 2016 Aug 10. Dis Markers. 2016. PMID: 27594734 Free PMC article. - Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis.
Araki K, Osaki M, Nagahama Y, Hiramatsu T, Nakamura H, Ohgi S, Ito H. Araki K, et al. Cancer Sci. 2005 Apr;96(4):227-31. doi: 10.1111/j.1349-7006.2005.00033.x. Cancer Sci. 2005. PMID: 15819721 Free PMC article. - Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis.
Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Ho SM. Wu T, et al. Br J Cancer. 2011 Jun 28;105(1):65-73. doi: 10.1038/bjc.2011.143. Epub 2011 Jun 7. Br J Cancer. 2011. PMID: 21654682 Free PMC article. - RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking.
Wolff EM, Liang G, Cortez CC, Tsai YC, Castelao JE, Cortessis VK, Tsao-Wei DD, Groshen S, Jones PA. Wolff EM, et al. Cancer Res. 2008 Aug 1;68(15):6208-14. doi: 10.1158/0008-5472.CAN-07-6616. Cancer Res. 2008. PMID: 18676844 Free PMC article. - DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer.
Delgado-Cruzata L, Hruby GW, Gonzalez K, McKiernan J, Benson MC, Santella RM, Shen J. Delgado-Cruzata L, et al. DNA Cell Biol. 2012 Feb;31(2):187-92. doi: 10.1089/dna.2011.1311. Epub 2011 Aug 10. DNA Cell Biol. 2012. PMID: 21830905 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous